About Curida
Curida is a Healthcare company based in Elverum (Norway) founded in 2015. Liquid pharmaceuticals are developed via blow fill seal technology. Curida has raised $3.2 million across 2 funding rounds from investors including Signet Healthcare Partners and Investinor. The company has 65 employees. Curida offers products and services including Small Molecules Formulations, Liquid Pharmaceuticals, Biologics, and Raw Material Services. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation.
Company details
Curida is a CDMO offering its services for the development of iquid dosage forms in formats such as blow fill seals, nasal sprays and bottles. More than 90 of Curidas revenues comes from their exports to 30 countries and they claim to have 40 years of experience in this field. Their development services portfolio includes formulation development, analytical method development and validation, stability studies, tech transfer and regulatory support. Curidas development services cater mainly to the development of nasal and inhalation drug products (OINDP) and other ophthalmic or topical products which are usually administered with the help of a delivery device.
- Annual Revenue$20.69 M (USD)47as on Dec 31, 2022
- Net Profit-$4.78 M (USD)-186as on Dec 31, 2022
- EBITDA-$3 M (USD)-511as on Dec 31, 2022
- Total Equity Funding$3.2M (USD)
in 2 rounds
- InvestorsSignet Healthcare Partners
& 1 more
- Employee Count65
Products & Services of Curida
Curida offers a comprehensive portfolio of products and services, including Small Molecules Formulations, Liquid Pharmaceuticals, Biologics, and Raw Material Services.
Develops formulations for safe medicine supply and manufacturing.
Produces liquid drugs using blow-fill-seal technology for sterile products.
Specializes in monoclonal antibodies production and conjugation services.
Provides raw materials and special pharmaceuticals for pharmacies.
Funding Insights of Curida
Curida has successfully raised a total of $3.2M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.2M
- Total Rounds 2
- First Round $3.2M
(Jan 2018)
- Investors Count 2
All 2 funding rounds of Curida with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | Seed | – | – | ||
| Jan 2018 | $3.2M | Seed | – | – |
2 investors in total: 2 institutional.
Investors in Curida
Curida has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Signet Healthcare Partners and Investinor.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in North America and Europe | signethealthcarepartners.com | New York, United States | ||
| investinor.no |
Investor details for Curida
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Curida
1 people are tracked at Curida (1 in team); the tracked headcount is 65.
| Name | Role | Group |
|---|---|---|
Ole J. Dahlberg | Chairperson Of The Board | Team |
Complete people profiles for Curida
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Curida
3 dated milestones of Curida across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Curida is founded.
- Funding First funding round of $3.2M.
- Funding Latest funding round, Seed,.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Curida
Complete news archive for Curida
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Curida
Curida was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Curida is headquartered in Elverum, Norway.
Curida is a funded company, having raised a total of $3.2M across 2 funding rounds to date. The company's 1st funding round was a Seed of $3.2M, raised on Jan 2018.
Curida has 65 employees.
Annual revenue of Curida is $20.69M as on Dec 31, 2022.
Curida is a CDMO offering its services for the development of iquid dosage forms in formats such as blow fill seals, nasal sprays and bottles. More than 90 of Curidas revenues comes from their exports to 30 countries and they claim to have 40 years of experience in this field. Their development services portfolio includes formulation development, analytical method development and validation, stability studies, tech transfer and regulatory support. Curidas development services cater mainly to the development of nasal and inhalation drug products (OINDP) and other ophthalmic or topical products which are usually administered with the help of a delivery device.
Curida offers Small Molecules Formulations, Liquid Pharmaceuticals, Biologics, and Raw Material Services.
Curida has 2 investors. Key investors include Signet Healthcare Partners, and Investinor.